Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPimavanserin (also known as ACP-103) is a selective, potent 5-HT2A receptor inverse agonist (IC50 = 2 nM). Pimavanserin displays ~ 40-fold higher affinity for 5-HT2A over 5-HT2C receptor. Chronic administration of Pimavanserin, suppresses amyloid-β production and improves anxiety-related behavior and memory in Alzheimer's disease mouse models. Pimavanserin shows protective effects on midbrain dopaminergic neurons in a rat model of Parkinson's Disease.
Pimavanserin is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 427.56 |
公式 | C25H34FN3O2 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 706779-91-1 |
PubChem ID | 10071196 |
InChI Key | RKEWSXXUOLRFBX-UHFFFAOYSA-N |
Smiles | O=C(NCC1=CC=C(OCC(C)C)C=C1)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 21.38 | 50 | |
ethanol | 42.76 | 100 |
以下数据基于产品分子量 427.56。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.34 mL | 11.69 mL | 23.39 mL |
5 mM | 0.47 mL | 2.34 mL | 4.68 mL |
10 mM | 0.23 mL | 1.17 mL | 2.34 mL |
50 mM | 0.05 mL | 0.23 mL | 0.47 mL |
参考文献是支持产品生物活性的出版物。
Snigdha et al (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J.Pharmacol.Exp.Ther. 332 622 PMID: 19864614
Yuede et al (2021) Pimavanserin, a 5HT 2A receptor inverse agonist, rapidly suppresses A beta production and related pathology in a mouse model of Alzheimer's disease. J.Neurochem. 156 658 PMID: 33278025
Gras Lavigne et al (2021) Pimavanserin promotes trophic factor release and protects cultured primary dopaminergic neurons exposed to MPP+ in a GDNF-dependent manner. ACS Chem.Neurosci. 12 2088 PMID: 34032411
Vanover et al (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptam J.Pharmacol.Exp.Ther. 317 910 PMID: 16469866
If you know of a relevant reference for Pimavanserin, please let us know.
关键词: Pimavanserin, Pimavanserin supplier, Potent, selective, high, affinity, 5-HT2A, agonists, receptors, serotonin, ACP-103, agonism, Receptors, 7667, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。
目前没有 Pimavanserin 的引用文献。 您是否知道使用了 Tocris Pimavanserin 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review Pimavanserin and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.